Advertisement
Advertisement
Trending on OncLive
1
Analysis Identifies Potential Response, Resistance Biomarkers to Mogamulizumab in R/R Mycosis Fungoides/Sézary Syndrome
2
Tofacitinib 2% Cream Yields Responses and Is Safe in Mycosis Fungoides
3
A Randomized Phase III Study Evaluating Izalontamab Brengitecan (Iza-bren) Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
4
Dr Beylot-Barry on Moga-Stop, Mogamulizumab Retreatment in Sézary Syndrome
5